The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). One of the leading cannabis clinicians in the U.S.,

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JANUARY 27, 2020

We take a look at where CBD regulation might be going and whether we should be concerned about safety writes Rob Verkerk PhD, scientific and executive director, ANH-Intl. We take a look at where CBD regulation might be going and whether we should be concerned about safety. A new ‘problem’: safety. ? A new ‘problem’: safety.

Safety 59

Safety CBD Food Seed-To-Sale 59

Veriheal

NOVEMBER 18, 2022

According to the Texas Department of Public Safety Chief Wayne Muller, the state has averaged a 10% month-over-month increase in medical cannabis patients over the last 18 months. Back in 2019 , the program was expanded to include ALL individuals with epilepsy—not just those with intractable epilepsy as the program had originally outlined.

Edibles 98

Edibles Hemp Epilepsy Programs 98

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Epilepsy Behav. Consumers spent roughly $31.3 increase in annual sales.

CBD 144

CBD Seed-To-Sale Food Access 144

TheAnswerPage

JULY 17, 2022

In 2017, researchers performed an analysis of observational clinical studies on the treatment of refractory epilepsy with cannabidiol (CBD)-based products. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis Front. 12 September 2018.

Epilepsy 56

Epilepsy Extraction Treatment CBD 56

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. federal law.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Cannabis Law Report

AUGUST 5, 2019

The two-year experiment is being overseen by the French Agency for Drug Safety (ANSM), which drew up a 13-name committee to explore the possibilities of reform in one of Europe’s largest markets in December 2018. France is searching for patients to take part in an official medical cannabis trial, but users will not be smoking the drug.

Medicine 60

Medicine Patients Digestion Epilepsy 60

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

Cannabis Law Report

JUNE 5, 2019

The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Today (30 May) at 09.30 The organization will focus on the use of special treatment schemes.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Freedom Leaf

OCTOBER 15, 2018

On the basis of their review, the agency approved Epidiolex for use in treating rare forms of childhood epilepsy (Lennox-Gastaut syndrome and Dravet syndrome). Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S. will top $1.9 billion by 2022.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

MMJ Recs

NOVEMBER 17, 2023

MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more. Seizure Control: For patients with epilepsy and seizure disorders, certain cannabis-based treatments have shown remarkable effectiveness in reducing the frequency and severity of seizures.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

The Joint Blog

JANUARY 23, 2020

. “Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known.”

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

The Joint Blog

MARCH 16, 2020

For the study researchers examined the use of marijuana over a 12-month period in a cohort of patients with chronic diseases, such as HIV, epilepsy, and fibromyalgia. The aim of the study was to assess the psychological safety and QoL of patients with chronic diseases who self-medicate with cannabis over time.

Patients 49

Patients Marijuana Epilepsy Treatment 49

Cannabis Law Report

DECEMBER 11, 2021

The clinic established the UK Medical Cannabis Registry to offer patients medical cannabis products at a reduced price while collecting and analysing clinical data from real-world evidence “to expand our understanding of medical cannabis in the UK”. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

Canna Law Blog

JUNE 5, 2019

The objective of the meeting was to gather scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of these products. Others stressed the need to adopt terminology, manufacturing and standards for these products in order to protect the consumer and avoid a public health crisis.

CBD 56

CBD Hemp Food Agriculture 56

WeedAdvisor

APRIL 1, 2019

As anecdotal evidence began piling up, some companies decided that CBD’s reported effects on epilepsy (which has been heavily proven), anxiety, insomnia, pain and inflammation – among others – could work on dogs, cats and other pets. Due to safety and legal concerns, we do not condone the use of illegal or unapproved cannabis products.

Pets 49

Pets Oil CBD Research and Development 49

Otherside Farms

FEBRUARY 14, 2019

billion by 2020; the World Anti-Doping Agency eliminated the CBD from its list of banned substances; The Food and Drug Administration (FDA) for the first time approved a drug for epilepsy that contained CBD oil, prompting the US Drug Enforcement Administration to change its position about the CBD. billion dollars by 2022, with 1.3

CBD 65

CBD Legalization Hemp Chronic Pain 65

Cannabis Law Report

MAY 10, 2019

Use of vape oil reduces the risk of side effects of epilepsy and treats any complications linked to epilepsy-like psychiatric disease, neurodegeneration and neuronal injury. There is a lack of safety data availability. Using these oils reduces symptoms like anxiety, mood-related symptoms, insomnia and pain.

Vaping 45

Vaping Oil CBD Epilepsy 45

The Cannigma

JUNE 29, 2021

It’s also the most appropriate for medical conditions such as depression , epilepsy , and autism spectrum disorder. But from a clinical perspective, we know almost nothing about this type of cannabis — either about its safety or its efficacy. Other cannabis chemotypes. Type V: Zero cannabinoids.

Terpenes 138

Terpenes Research and Development Cannabinoids Concentrates 138

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. Initially, he refused their requests due to insufficient data, however the evidence shown by a recent study done in Israel on CBD managing epilepsy was enough to sway him in the other direction.

Treatment 76

Treatment Oil CBD Therapy 76

WeedAdvisor

AUGUST 26, 2019

While the law currently only allows for CBD products to be imported by licensed patients with severe epilepsy, this could soon change. Eligible recipients can import a fixed amount of cannabis every year, at which point the prescription would require renewal. The THC Controversy. .

Strains 45

Strains Cultivation THC Epilepsy 45

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g.,

CBD 40

CBD Research and Development Safety Therapy 40

Puff Puff Post

DECEMBER 2, 2019

The FDA’s Consumer Update reiterated that, with the exception of Epidiolex (a CBD drug for rare forms of epilepsy), the FDA hasn’t approved any other forms of CBD. This is mainly due to a lack of data. This includes cases in which CBD products were tested and found to have less Cannabidiol than claimed.

CBD 52

CBD Food Pets Safety 52

Cannabis Law Report

JANUARY 13, 2020

Advance the medical literature regarding Epidiolex through publications in top-tier medical journals and at major scientific and medical meetings, notably the American Academy of Neurology and American Epilepsy Society meetings. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

MAY 19, 2022

FDA states it has serious safety concerns with delta-8 THC. FDA considers delta-8 THC to pose serious health and safety risks. Many CBD users have reported improvements in: Stress; Anxiety; Sleep; Pain levels; Skin conditions including acne and eczema; Epilepsy”. In particular, FDA highlighted the following –. Moving Forward.

THC 52

THC CBD Food Pets 52

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults. First Patient Expected to be Enrolled by Q2 of 2022.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

The Joint Blog

JULY 14, 2021

There has been inadequate research conducted and not enough data that fully supports the use of CBD for the elderly. Older people with underlying conditions such as kidney disease, liver disease, epilepsy, weak immune system, and heart issues should mention it to the doctor before using CBD. The dangers of CBD Products to the Elderly.

Medicine 52

Medicine CBD Chronic Pain Oil 52

Cannabis Law Report

MAY 6, 2022

The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Taking CBD can relieve pain.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

DECEMBER 8, 2021

This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. The results of this study underscore the safety of our spray film technology.”. This is an important step in the development of Epoladerm and further prepares us for expected clinical trials,” commented Anthony P.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Weedistry

MARCH 8, 2019

In 2018, medical cannabis became legal in the UK after a nationwide outpouring of support for two young boys who rely on cannabis oil to treat their severe and rare forms of epilepsy, but lingering concerns around the safety and efficiency of the medicine mean that access is still heavily restricted. THC – between 2015 and 2017.

Oil 40

Oil Treatment Patients THC 40

Cannabis Law Report

JUNE 1, 2021

Director of Medical Affairs and a Product Development Team lead at Greenwich Biosciences, where he played an important role in the complex, successful commercialization of the first cannabis-based product approved by the FDA to treat rare forms of epilepsy. Cautionary Note on Forward-Looking Statements.

Research and Development 51

Research and Development Treatment Pharmaceutical Patients 51

Cannabis Law Report

NOVEMBER 10, 2021

as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. Once the Envelta IND-enabling studies are submitted to the FDA, the data may be cross-referenced to our cancer pain and PTSD INDs. About Virpax Pharmaceuticals. For more information, please visit www.virpaxpharma.com.

Research and Development 40

Research and Development Chronic Pain Pharmaceutical Clinical Trials 40

The Cannigma

DECEMBER 22, 2021

Listen & Subscribe: Israel is world-renowned for the research and innovation that is taking place there, and unofficial data suggests that around 20% of the Israeli population uses cannabis. We have autism and epilepsy. It has the – you assume safety, at least to a certain level. EG: The population as well.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Cannabis Law Report

MAY 17, 2019

million increase from 2019 and over double the DEA’s $2.862 billion budget), the FDA is responsible for protecting and promoting public health through controlling and supervising food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, cosmetics, animal foods and feed, and veterinary products.

Food 10

Food DEA Hemp CBD 10